Allometric pharmacokinetic scaling: Towards the prediction of human oral pharmacokinetics

Pharmaceutical Research

Volumn 17, Issue 4, 2000, Pages 410-418

  Feng, Meihua Rose ^a   Lou, Xiaochun ^a   Brown, Richard R ^a   Hutchaleelaha, Athiwat ^b  

^a PFIZER INC   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Allometric scaling; Interspecies scaling; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B; CAFFEINE; CEFAZOLIN; CEFODIZIME; CEFOPERAZONE; CEFOTETAN; CEFPIRAMIDE; CEFTIZOXIME; CIPROFLOXACIN; DIAZEPAM; ENPROFYLLINE; LATAMOXEF; MIBEFRADIL; MIDAZOLAM; MOFAROTENE; PHENAZONE; PROPRANOLOL; REMOXIPRIDE; SEMATILIDE; TAMSULOSIN; THEOPHYLLINE; VALPROIC ACID;

ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BRAIN WEIGHT; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; HUMAN; PRIORITY JOURNAL;

AREA UNDER CURVE; HUMANS; MOUTH; PHARMACOKINETICS; RETROSPECTIVE STUDIES;

EID: 0034120946     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007520818956     Document Type: Article

References (30)

1. 1. H. Boxenbaum. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmcokin. Biopharm. 2, 165-176 (1980).
2. 2. H. Boxenbaum. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev. 15:1071-1121 (1984).
3. 3. H. Boxenbaum, Time concepts in physics, biology, and pharmacokinetics. J. Pharm. Sci. 75:1053-1062 (1986).
4. 4. H. Boxenbaum and C. Dilea. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol. 35: 957-966 (1995).
5. 5. M. Rose Feng, J. Loo, and J. Wright. Disposition of the antipsychotic CI-1007 in rat, monkey, dog, and human CYP2D6 extensive metabolizers: species comparison and allometric scaling. Drug Metab. Dispos. 10:982-988 (1998).
6. 6. M.R. Feng, D. Rossi, C. Strenkoski, A. Black, P. DeHart, M. Lovdahl, and William McNally. Disposition of cobalt mesoporphyrin in mice, rat, monkey, and dog. Xenobiotica 4:413-426 (1998).
7. 7. G. Robbie and W. L. Chiou. Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm. Res. 10: 1630-1636 (1998).
8. 8. I. Mahmood, and J. Balian. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895 (1996)
9. 9. I. Mahmood. Interspecies scaling: predicting clearance of anticancer drugs in humans. Eur. J. Drug Metab. Pharmacokin. 3: 275-278 (1996).
10. 10. G. Robbie and W. L. Chiou. Elucidation of human amphotericin B pharmacokinetics: Identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm. Res. 10: 1630-1636 (1998).
11. 11. W. L. Chiou, G. Robbie, S. Chung, T. Wu, and C. Ma. Correlation of plasma clearance of 54 extensively metabolized drugs between human and rats: mean allometric coefficient of 0.66. Pharm. Res. 9:1474-1479 (1998).
12. 12. Sanford Bolton. In James Swarbrick (ed), Pharmaceutical statistics: practical and clinical applications. Marcel Dekker Inc. New York. 1997, p. 17.
13. 13. W. G. Richter, P. Heizmann, J. Meyer, V. Starke, and T. Lave. Animal Pharmacokinetics and interspecies scaling of Ro 25-6833 and related (Lactamylvinyl)cephalosporins. J. Pharm. Sci. 4: 496-500 (1998).
14. 14. H. Mataushita, H. Suzuki, Y. Sugiyama, etc. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J. Pharmacobio-Dyn. 13:602-611 (1990).
15. 15. J. Mordenti. Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J. Pharm. Sci. 10:1097-1099 (1985).
16. 16. A. Hutchaleelaha, H. Chow, and M. Mayerson. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J. Pharm. Pharrmacol. 49:178-183 (1997).
17. 17. T. Lave, S. Duoin, C. Schmitt, R. C. Chou, D. Jaeck, and P. Coassolo. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharm. Sci. 5:584-585 (1997).
18. 18. Y. Tsunekawa, T. Hasegawa, M. Nadai, K. Takagi, and T. Nabeshima. Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J. Pharm. Pharmacol. 44:594-599 (1992).
19. 19. P. Hinderling, C. Dilea, T. Koziol, and G. Millington. Comparative kinetics of sematilide in four species. Drug Metab. Dispos. 4:662-669 (1993).
20. 20. M. Widman, L. B. Nilsson, B. Bryske, and J. Lundström. Disposition of Remoxipride in different species. Arzneim-Forsch./Drug Res. 43:287-297 (1993).
21. 21. H. M. Siefert, D. Maruhn, W. Maul, D. Forster, and W. Ritter. Pharmacokinetics of ciprofloxacin. Arzneim-Forsch./Drug Res. 36:1496-1502 (1986).
22. 22. J. Nouws, D. Mevius, T. Vree, A. Baars, and J. Larenses. Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet. Quart. 3:156-163 (1988).
23. 23. In J. Hardman and L. Limbird (eds). Goodman & Gilman's: The Pharmacological Basis for Therapeutics. McGraw-Hill, New York. 1997, p. 1729.
24. 24. K, Nakagawa, M. Kouama, H. Matsui, C. Ikeda, K. Yano, N. Nakatsuru, K. Yoshinaga, and T. Noguchi. Pharmacokinetics of Cefpiramide (SM-1652) in humans. Antimicrob. Agents Chemother. 2:221-225 (1984).
25. 25. T. Lave, S. P. Coassolo, and B. Reigner. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro - in vivo correlation Clin. Pharmacokin. 3:211-231 (1999).
26. 26. Pahlman, M. Edholm, S. Kankaanranta and M.-L. Odell. Pharmacokinetics of Susalimod, a highly biliary-excreted sulphasalazine analogue, in various species. Nonpredictable human clearance by allometric scaling. Pharm. Pharmacol. Commun. 4:493-498 (1998).
27. 27. J. H. Lin. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 10:1008-1020 (1995).
28. 28. W. L. Chiou and A. Barve. Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats. Pharm. Res. 11:1792-1795 (1998).
29. 29. S. Yee. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. 14:763-766 (1997).
30. 30. R. S. Obach. Prediction of human clearance of twenty-nine drugs from hepatic micosomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 11:1350-1359 (1999).